Literature DB >> 9302743

Manipulation of HIV-1 gp120-specific immune responses elicited via gene gun-based DNA immunization.

S K Prayaga1, M J Ford, J R Haynes.   

Abstract

Gene gun-based DNA immunization using vectors encoding HIV-1 gp120 or influenza virus nucleoprotein result in Th2-like immune responses following successive immunizations. The codelivery of vectors encoding IL-2, IL-7, or IL-12 blocked this effect by markedly enhancing gp120-specific interferon gamma production, and suppressing IL-4 and IgG1 responses. An unbiased augmentation of all immune responses was observed by increasing the resting period between immunizations. In this case, IFN-gamma production following in vitro stimulation increased by over 1000-fold, while IL-4, IgG1, and IgG2a responses were elevated as well. Interestingly, cytokine gene codelivery, in the context of the longer resting period, provided no additional stimulation of Th1-like responses such as IFN-gamma and IgG2a production, although there was still some suppression of IL-4 production. These data demonstrate that the quality and magnitude of responses elicited following epidermal administration of DNA vaccines can be manipulated by multiple means.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9302743     DOI: 10.1016/s0264-410x(97)00036-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  DNA-antiviral vaccines: new developments and approaches--a review.

Authors:  M Giese
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

2.  Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates.

Authors:  M J McCluskie; C L Brazolot Millan; R A Gramzinski; H L Robinson; J C Santoro; J T Fuller; G Widera; J R Haynes; R H Purcell; H L Davis
Journal:  Mol Med       Date:  1999-05       Impact factor: 6.354

Review 3.  DNA and RNA-based vaccines: principles, progress and prospects.

Authors:  W W Leitner; H Ying; N P Restifo
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

4.  Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.

Authors:  E J Verschoor; P Mooij; H Oostermeijer; M van der Kolk; P ten Haaft; B Verstrepen; Y Sun; B Morein; L Akerblom; D H Fuller; S W Barnett; J L Heeney
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

5.  Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice.

Authors:  Masanori Matsui; Osamu Moriya; Maria Laura Belladonna; Sadahiro Kamiya; François A Lemonnier; Takayuki Yoshimoto; Toshitaka Akatsuka
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1.

Authors:  K Q Xin; K Hamajima; S Sasaki; A Honsho; T Tsuji; N Ishii; X R Cao; Y Lu; J Fukushima; P Shapshak; S Kawamoto; K Okuda
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

7.  Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines.

Authors:  Joshua Arrington; Ralph P Braun; Lichun Dong; Deborah H Fuller; Michael D Macklin; Scott W Umlauf; Sarah J Wagner; Mary S Wu; Lendon G Payne; Joel R Haynes
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.